The science agenda for the CPCRA focuses on answering key clinical management questions that face providers and patients every day. The agenda is constructed around a core of antiretroviral treatment trials. These trials are complemented with substudies and other trials focused on issues of current interest. The following diagram illustrates how the studies are interconnected.
In the diagram, the core antiretroviral strategy trials are represented by yellow boxes in the center of the figure. The levels of studies target persons in different stages of a disease.
The Flexible Initial Retroviral Suppression Trial (FIRST; CPCRA 058) targets persons who are initiating therapy while Nelfinavir versus Ritonavir (NvR; CPCRA 042) targets those who are beginning their first protease inhibitor (PI).
The SMART* study explores strategic options to antiretroviral use.
The Multidrug-Resistant (MDR-HIV; CPCRA 064) study targets persons with progressive disease due to multi-drug resistant virus.
The Long-Term Monitoring (LTM; CPCRA 060) study targets patients at any stage of disease and treatment and provides a means of monitoring patients over years of follow-up, seeking data on the late outcomes of clinical therapy.